Long Term Follow-Up Adult Long Bone Osteomyelitis Managed with the Modified Lautenbach Procedure 

Description

This transcript captures a presentation by Andrew McCaskie discussing the challenges and considerations surrounding the use of mesenchymal stem cells (MSCs) for treating knee osteoarthritis. He points out that clinical evidence supporting the efficacy of MSCs in this context is currently limited, which contributes to confusion and frustration within the scientific community. McCaskie emphasizes the importance of building consensus on terminology and definitions related to stem cells and their applications, advocating for a standardized approach to research and treatment.



He references collaborative efforts with others in the field to clarify misconceptions and improve scientific understanding, mentioning several significant publications, including a report from *Nature*. McCaskie proposes a structured way of categorizing cell therapies, outlining essential aspects such as donor type, separation methods, and delivery routes to facilitate better comparisons among studies.



The discourse also touches on regulatory aspects of advanced therapeutic medicinal products and the push for point-of-care manufacturing, promoting innovative treatment development while ensuring safety and efficacy. McCaskie underscores the critical need for strong preclinical evidence before clinical application and calls for rigorous evaluation through well-designed clinical trials.



In the Q&A portion, McCaskie is asked about practical advice for those considering using fat-derived stem cells for knee injections. He compares the current landscape of stem cell therapies to the early days of arthroplasty, emphasizing the necessity for substantial evidence and a clear understanding of treatment goals before implementation, advocating for evidence-based practices.

Specialties